Children's Hospital of Philadelphia leads or participates in hundreds of clinical trials. Use this database to learn the purpose of these trials, find out who can participate and more.
11 - 20 of 165
We are conducting a research study on the genetics of PHACE Syndrome. The purpose of this study is to develop a better understanding of the cause of PHACE Syndrome by collecting DNA in the forms of cells from skin biopsies, tissue specimens, blood samples, and/or buccal swabs. Individuals (any age) or family members of patients with PHACE Syndrome or a large segmental hemangioma can participate. What we learn from this study will help us to provide individuals with PHACE syndrome and their relatives more detailed and accurate information about the etiology of the disease. IRB 16-013503
The purpose of this research study is to find out if stem cells from umbilical cord blood (collected at birth) can strengthen the muscle of the right side of the heart for patients diagnoses with Hypoplastic Left Heart Syndrome who are scheduled to undergo the Glenn Surgical procedure. IRB 17-013819
Researchers want to find out if bardoxolone methyl, a drug being developed by Reata Pharmaceuticals, can improve Alport Syndrome, with its disease-modifying effects in kidney function. Bardoxolone methyl is an investigational (experimental) drug that is being tested, and is not currently approved by the U.S. Food and Drug Administration (FDA), or any other regulatory agency for sale in the United States or any other country. In this study, bardoxolone methyl will be given to approximately 210 patients with Alport Syndrome from approximately 60 study centers who are between the ages of 12 and 60. The trial will consist of two cohorts (i.e. groups). Cohort 1 is considered a Phase 2 study, and will enroll up to 30 subjects. Cohort 1 will be open-label where everyone involved in the study (including you) know that the study drug being used will ONLY be bardoxolone methyl capsules. CHOP will not be participating in Cohort 1.
Cohort 2 will be a double-blind, randomized, placebo-controlled, Phase 3 study, and will enroll up to 180 subjects. This means that you will be randomly assigned (like flipping a coin) to either bardoxolone methyl, or a placebo (i.e. inactive substance/sugar pill), and that both you AND your doctor will not know which drug you are assigned to. IRB 17-013989
The purpose of this study is to understand how motor function- the way we move our faces and bodies- impactssocial communication. We are seeking adolescents ages 12-17 with or without ASD or a mixed psychological diagnosis (ADD, ADHD, ODD, or anxiety). You will maketwo visits to CHOP and completeeasy activities related to movement and communication. Allparticipants will complete IQ and diagnostic testing. Parentswill be asked to complete questionnaires prior to their child’s visit and willcomplete interviews at the visit. Compensation and travel reimbursement will be provided.
Parent involvement is critical in child language development, learning and literacy. Our team is looking for parents of children under the age of 5 years to conduct parent-only focus groups to learn more about how parents think their behavior influences these developments and what they think their role in their child’s learning is. We are also aiming to better understand parents' thoughts on reading, interacting with their children and how technology factors into language development. Focus groups will last about 30-45 minutes, and will be held either at CHOP or in a local community setting in Philadelphia. All participants will be compensated for their time and insights.
The purpose of this research study is to test and adapt new techniques for performing magnetic resonance imaging (MRI). MRI provides pictures of the inside of the body and information about chemicals the body makes. Here are some examples of what we hope to accomplish:
1. Adapt MRI techniques used at other institutions for use on CHOP MRI scanners
2. Increase the amount of information learned from each MRI image
The research sequences involve changing the settings of the magnetic resonance scanner. By research sequences we mean that they are not approved by the US Food and Drug Administration (FDA) for clinical use. The data we obtain will help the FDA evaluate whether or not they can eventually approve the sequences for clinical use.
We are seeking to enroll healthy volunteers, 18 years of age and above. Pregnant females excluded for safety purposes.
The purpose of this study is to identify and engage young black or hispanic/latino men (male sex at birth, but gender identity male, transfemale, or gender nonconforming) (YBLMSM/transwomen) in Philadelphia, PA, Baltimore, MD and Washington, DC in HIV and substance use prevention using a new Mobile-enhanced Engagement intervention (app that reminds you to take your meds, reminds you of your medical appointments, etc.). There are three different parts to this study: 1) respondent driven sampling (RDS); 2) Randomized Control Trial (RCT): MEI vs Standard of Care for HIV+ youth; and 3) PrEP RCT: Pre Exposure Prophylaxis - Mobile-enhanced Engagement Intervention (PrEP-MEI) vs. Standard PrEP referral;. It is possible to participate in only the RDS, the RDS and the AIM 3 PrEP RCT, or the RDS and AIM 2 RCT studies.
The RDS study involves 2 study visits lasting up to 1 month of participation where participants will be asked to complete an optional rapid HIV test (oral or fingerstick) or viral load testing (blood draw), web-based survey (on past sexual and HIV experiences), recruit your peers to participate in the study, and complete a post-recruitment survey. YBLMSM/transwomen and cisgender females 15-24 years may participate in RDS, but the following study portions are only for YBLMSM/transwomen:
People who successfully complete the RDS portion of the study may be asked to participate in an additional study visit of an audio-recorded focus group or interview.
The RCT study involves 6 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different HIV supportive interventions: 1) HIV case management with a Mobile-enhanced Engagement Intervention (MEI), or 2) standard of care HIV case management where a case manager will remind you of medical appointments. If you are assigned to the first group (MEI), you will be asked to use the MEI mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody and Viral load testing (blood draw), urine drug testing, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.
The PrEP RCT study involves 5 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different PrEP and substance use supportive interventions: 1) PrEP case management with a Mobile-enhanced Engagement Intervention (MEI-PrEP), or 2) standard PrEP referrals to services. If you are assigned to the first group (MEI-PrEP), you will be asked to use the MEI-PrEP mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody (blood draw or 2 rapid OraQuick tests in place of serologic 4th generation testing when 4th generation testing is not available) and Viral load testing (blood draw), urine drug testing, use the MEI-PrEP mobile app or web-browser version of the app, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.
The purpose of the study is to study the effect of adenotonsillectomy surgery (removal of tonsils and adenoids) in mild disordered breathing. All participants in the study will be evaluated for surgery because adenotonsillectomy is a commonly used treatment for MSDB; however, one group will get surgery early (within one month after a sleep study) and the other group will be observed without surgery for 12 months. After 12 months, subjects who did not get surgery may be reevaluated for surgery by the ear, nose and throat doctor to decide whether they should get surgery or not. Following confirmation of initial eligibility including a screening sleep study, participants will undergo the following procedures: urine collection for cotinine, medical history and physical examination including blood pressure and anthropometry, behavioral testing, questionnaire completion by parent, venipuncture, actigraphy. If subjects have questions or concerns about the study Dr. Ignacio Tapia (PI) Laurie Karamessinis 215-590-9184 research coordinator, and Mary Anne Cornaglia, research coordinator can be reached at 215-590-3749 or 267-426-5748.
We are testing to see if basic brain functions are related to how someone will drive in a simulator. If you participate, you will complete some questionnaires on everyday behaviors and driving behaviors; complete some computer-based tests on memory, self-control, and mental flexibility; and then drive in our driving simulator. We will then compare your simulated drive performance with your cognitive test results to see which components of cognition contribute to driving ability. You will receive compensation for your time, effort and inconvenience.
The Division of Rheumatology at CHOP is looking to engage healthy participants for several research studies with the goal of learning more about ways to improve the health and wellbeing of children and young adults. Participants may be asked to come for a one time study visit at CHOP, complete hand-eye coordination tests and/or a sensation threshold test, complete a survey, and/or additional study procedures.